Boxer Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Boxer Capital’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-60,714	Closed	-$4.25M	–	29
2018 Q3	$4.25M	Hold	60,714	–	–	0.47%	19
2018 Q2	$4.5M	Hold	60,714	–	–	0.51%	22
2018 Q1	$5.78M	Buy	60,714 +22,857	+60%	+$3.92M	0.62%	24
2017 Q4	$4.89M	Buy	37,857 +8,571	+29%	+$803K	0.89%	20
2017 Q3	$1.99M	Hold	29,286	–	–	0.45%	24
2017 Q2	$2.77M	Buy	29,286 +14,286	+95%	+$1.64M	0.66%	21
2017 Q1	$2.15M	Hold	15,000	–	–	0.47%	22
2016 Q4	$1.9M	Buy	+15,000	New	+$2.09M	0.74%	16

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Boxer Capital's VIRX Position: Q4 2018 in Review

Boxer Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2018, closing a stake of 60,714 shares — an estimated $4.25M sold.

Boxer Capital first reported a position in VIRX in Q4 2016 and held it in 8 quarters. The position peaked at $5.78M in Q1 2018. 40 funds tracked by Wall St. Rank hold VIRX as of Q4 2018.

Boxer Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Boxer Capital sold 60,714 Viracta Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $4.25M.
Boxer Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2016 and held it in 8 quarters.
Boxer Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $5.78M in Q1 2018.
40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Boxer Capital's 13F filing for Q4 2018, filed 14 Feb 2019.